ADC Therapeutics SA (NYSE:ADCT) Receives Average Rating of “Buy” from Analysts

Shares of ADC Therapeutics SA (NYSE:ADCTGet Rating) have been assigned a consensus recommendation of “Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $41.60.

A number of equities analysts recently commented on the company. Morgan Stanley raised their target price on ADC Therapeutics from $29.00 to $30.00 and gave the company an “overweight” rating in a report on Tuesday. HC Wainwright lowered their target price on ADC Therapeutics from $55.00 to $54.00 and set a “buy” rating for the company in a report on Friday, March 4th. Finally, Zacks Investment Research upgraded ADC Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, January 21st.

Hedge funds have recently bought and sold shares of the business. Dark Forest Capital Management LP acquired a new stake in shares of ADC Therapeutics during the 3rd quarter worth about $25,000. Lazard Asset Management LLC acquired a new stake in shares of ADC Therapeutics during the 4th quarter worth about $37,000. Indie Asset Partners LLC raised its position in shares of ADC Therapeutics by 6.3% during the 3rd quarter. Indie Asset Partners LLC now owns 97,411 shares of the company’s stock worth $2,646,000 after acquiring an additional 5,770 shares in the last quarter. Citadel Advisors LLC raised its position in shares of ADC Therapeutics by 57.3% during the 3rd quarter. Citadel Advisors LLC now owns 19,346 shares of the company’s stock worth $525,000 after acquiring an additional 7,047 shares in the last quarter. Finally, TD Asset Management Inc. raised its position in shares of ADC Therapeutics by 9.5% during the 3rd quarter. TD Asset Management Inc. now owns 92,290 shares of the company’s stock worth $2,507,000 after acquiring an additional 8,000 shares in the last quarter. 47.78% of the stock is currently owned by institutional investors.

NYSE ADCT opened at $14.19 on Friday. The stock has a market cap of $977.55 million, a PE ratio of -4.73 and a beta of 1.93. The company has a current ratio of 7.10, a quick ratio of 6.95 and a debt-to-equity ratio of 0.75. ADC Therapeutics has a twelve month low of $12.38 and a twelve month high of $32.00. The stock has a fifty day simple moving average of $14.76 and a 200-day simple moving average of $19.66.

ADC Therapeutics (NYSE:ADCTGet Rating) last announced its earnings results on Thursday, March 3rd. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.42. The firm had revenue of $17.01 million for the quarter, compared to analysts’ expectations of $16.40 million. During the same quarter last year, the business earned ($0.73) earnings per share. Research analysts predict that ADC Therapeutics will post -3.38 EPS for the current year.

ADC Therapeutics Company Profile (Get Rating)

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL).

Further Reading

Analyst Recommendations for ADC Therapeutics (NYSE:ADCT)

Receive News & Ratings for ADC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.